Cibus (NASDAQ:CBUS) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Cibus from “Sell” to “Hold,” while Weiss Ratings maintained a “Sell (e+)” rating. The stock’s overall analyst consensus is “Hold,” with a $9.00 price target.
• Cibus shares recently traded at $1.71, up 4.9%, but the company reported a quarterly loss of $0.29 per share and revenue of $0.99 million, both below analyst expectations.
• Institutional investors and hedge funds own 33.81% of Cibus, with several firms recently initiating or increasing positions in the agricultural biotechnology company.

Cibus (NASDAQ:CBUS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Cibus in a research note on Friday, September 25th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cibus currently has an average rating of "Hold" and a consensus price target of $9.00.

Cibus Trading Up 4.9%

CBUS opened at $1.71 on Friday. The stock's 50-day moving average price is $1.69 and its 200 day moving average price is $1.66. Cibus has a 12-month low of $1.09 and a 12-month high of $4.19. The firm has a market cap of $130.69 million, a price-to-earnings ratio of -1.04 and a beta of 1.57.

Cibus (NASDAQ:CBUS - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.10). The firm had revenue of $0.99 million for the quarter, compared to analysts' expectations of $1.70 million. Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%. On average, research analysts forecast that Cibus will post -1.13 earnings per share for the current year.

Institutional Trading of Cibus

Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Cibus in the first quarter worth approximately $33,000. Rockland Trust Co. purchased a new stake in shares of Cibus in the 2nd quarter valued at approximately $41,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Cibus in the 1st quarter valued at approximately $66,000. BDT Capital Partners LLC raised its holdings in shares of Cibus by 1,899.7% in the 4th quarter. BDT Capital Partners LLC now owns 63,410 shares of the company's stock valued at $110,000 after purchasing an additional 60,239 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Cibus by 324.2% during the 1st quarter. Bank of America Corp DE now owns 74,358 shares of the company's stock worth $147,000 after purchasing an additional 56,830 shares during the last quarter. Institutional investors and hedge funds own 33.81% of the company's stock.

Cibus Company Profile

Cibus, Inc is an agricultural biotechnology company that develops gene-edited traits for crops. Its technology is designed to make targeted changes to plant genetics without introducing foreign DNA, with the goal of improving crop performance, productivity and sustainability.

The company's proprietary Rapid Trait Development System (RTDS) platform is used to develop traits for the global seed industry. Cibus has focused on crops including canola, soybean and rice, pursuing applications such as improved disease resistance, herbicide tolerance, reduced pod shatter and other traits intended to support farmers and seed companies.

Founded in 2001, Cibus became a publicly traded company following its 2023 merger with Calyxt, Inc The company is headquartered in San Diego, California, and works with agricultural and seed-industry partners to advance and commercialize gene-edited crop traits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.